

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Finasteride effect as a treatment for chronic and recurrent central serous Chorioretinopathy(CSC)

#### Protocol summary

##### Summary

purpose: determination of finasteride effect as a treatment for chronic and recurrent central serous retinopathy(CSC) in patients refer to Baghaeepour polyclinic ,Shaheed Sadoughi hospital study design: before-after, non-randomized, single-center, prospective, uncontrolled, unmasked sample: patients refer to Baghaeepour polyclinic ,Shahid Sadoughi hospital inclusion criteria: patients with chronic CSCR, which was defined in this study as 1) the presence of subretinal fluid, as determined by spectral domain OCT; 2) the subretinal fluid must have been present for at least 3 months or there was a recurrence of subretinal fluid in ipsilateral eye within the past 3 months. exclusion criteria: corticosteroid use, CNV or other ocular disease that disturb the study outcome, pregnant and nursery women sample size: 30 intervention: finasteride tablet 5mg /daily up to 3 months outcome measurement: best corrected visual acuity, center-subfield thickness ,central subretinal fluid

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2013083114530N1**  
Registration date: **2014-01-31, 1392/11/11**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2014-01-31, 1392/11/11

##### Registrant information

##### Name

Tahere Rezaee

##### Name of organization / entity

Shahid Sadoughi University of Medical Science

##### Country

Iran (Islamic Republic of)

##### Phone

+98 35 1828 6410

##### Email address

t.rezaee@ssu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Shahid Sadoughi University of Medical science

##### Expected recruitment start date

2013-08-23, 1392/06/01

##### Expected recruitment end date

2014-08-22, 1393/05/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Finasteride effect as a treatment for chronic and recurrent central serous Chorioretinopathy(CSC)

##### Public title

Finasteride effect as a treatment for spontaneous retinal edema

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Eligibility criteria: patients with chronic CSCR, which was defined in this study as 1) the presence of subretinal fluid, as determined by spectral domain OCT; 2) the subretinal fluid must have been present for at least 3 months or there was a recurrence of subretinal fluid in ipsilateral eye within the past 3 months. exclusion criteria: corticosteroid use, CNV or other ocular disease that disturb the study outcome, pregnant and nursery

women

**Age**  
No age limit

**Gender**  
Both

**Phase**  
1-2

**Groups that have been masked**  
*No information*

**Sample size**  
Target sample size: **30**

**Randomization (investigator's opinion)**  
N/A

**Randomization description**

**Blinding (investigator's opinion)**  
Not blinded

**Blinding description**

**Placebo**  
Not used

**Assignment**  
Single

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

**Name of ethics committee**

Shahid Sadoughi University of Medical Science, Ethics Committee

**Street address**

Shahid Sadoughi University of Medical Science,  
Hesabi prof. boulevard, Daneshjoo boulevard

**City**

Yazd

**Postal code**

**Approval date**

2013-12-18, 1392/09/27

**Ethics committee reference number**

p/17/1/186945

## Health conditions studied

### 1

**Description of health condition studied**

Central Serous Chorioretinopathy

**ICD-10 code**

H35.7

**ICD-10 code description**

Separation of retinal layers

## Primary outcomes

### 1

**Description**

best corrected visual acuity

**Timepoint**

by the intervention initiation, 15 days, 1, 2 and 3 months after intervention, 3 months after discontinuation of intervention

**Method of measurement**

Snellen chart

### 2

**Description**

central macular thickness

**Timepoint**

by the intervention initiation, 15 days, 1, 2 and 3 months after intervention, 3 months after discontinuation of intervention

**Method of measurement**

spectral domain OCT

### 3

**Description**

subretinal fluid volume

**Timepoint**

by the intervention initiation, 15 days, 1, 2 and 3 months after intervention, 3 months after discontinuation of intervention

**Method of measurement**

spectral domain OCT

## Secondary outcomes

### 1

**Description**

adverse effects (decreased libido, impotence, improper ejaculation, postural hypotension, dizziness)

**Timepoint**

15 days, 1, 2 and 3 months after intervention

**Method of measurement**

patient history taking

## Intervention groups

### 1

**Description**

finasteride 5 mg tablet, 1 tablet per day up to 3 months (intervention group) no control group

**Category**

Treatment - Drugs

## Recruitment centers

### 1

**Recruitment center**

**Name of recruitment center**

Baghaee Pour clinic, Shahid Sadoughi hospital

**Full name of responsible person**

Tahere Rezaee

**Street address**Shahid Sadoughi hospital, Ebnesina boulevard,  
Safaeiye**City**

Yazd

t.rezaee@yahoo.com

**Web page address****Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shahid Sadoughi University of Medical Science

**Full name of responsible person**

dr. Vakili

**Street address**Shahid Sadoughi University of Medical Science,  
Hesabi prof. boulevard, Daneshjoo boulevard,**City**

Yazd

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Sadoughi University of Medical Science

**Proportion provided by this source**

100

**Public or private sector***empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Name of organization / entity**

Shahid Sadoughi University of Medical Science

**Full name of responsible person**

Tahere Rezaee

**Position**

Ophthalmology resident

**Other areas of specialty/work****Street address**Shahid Sadoughi hospital, Ebnesina boulevard,  
Safaeiye**City**

Yazd

**Postal code****Phone**

+98 35 1822 4000

**Fax**

+98 35 1822 4100

**Email****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shahid Sadoughi University of Medical Science

**Full name of responsible person**

Tahere Rezaee

**Position**

Ophthalmology resident

**Other areas of specialty/work****Street address**Shahid Sadoughi hospital, Ebnesina boulevard,  
Safaeiye**City**

Yazd

**Postal code****Phone**

+98 35 1811 3220

**Fax**

+98 35 1822 4100

**Email**

t.rezaee@ssu.ac.irt.rezaee@yahoo.com

**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Shahid Sadoughi University of Medical Science

**Full name of responsible person**

Tahere Rezaee

**Position**

Ophthalmology resident

**Other areas of specialty/work****Street address**Shahid Sadoughi hospital, Ebnesina boulevard,  
Safaeiye**City**

Yazd

**Postal code****Phone**

+98 35 1822 4000

**Fax**

+98 35 1822 4100

**Email**

t.rezaee@yahoo.com

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*